

European Journal of Clinical Pharmacology

Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers

--Manuscript Draft--

Manuscript Number:	EJCL-D-17-00690	
Full Title:	Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers	
Article Type:	Original Article	
Section/Category:	Pharmacokinetics and Disposition	
Funding Information:	Turku University Hospital research fund (FI) (EVO grants 13693 and 13821)	Dr Teijo Saari
Abstract:	<p>Purpose: Palliative care patients often need sedation to alleviate intractable anxiety, stress and pain. Dexmedetomidine is used for sedation of intensive care patients, but there is no prior information on its subcutaneous (SC) administration, a route that would be favored in palliative care. We compared the pharmacokinetics and cardiovascular, sympatholytic and sedative effects of SC and intravenously (IV) administered dexmedetomidine in healthy volunteers.</p> <p>Methods: An open two-period, cross-over design with balanced randomization was used. Ten male subjects received 1 µg/kg dexmedetomidine both IV and SC. Concentrations of dexmedetomidine and catecholamines in plasma were measured. Pharmacokinetic variables were calculated with non-compartmental methods. In addition, cardiovascular and sedative drug effects were monitored.</p> <p>Results: Peak concentrations of dexmedetomidine were observed 15 min after SC administration (median; range 15-240). The mean bioavailability of SC dexmedetomidine was 81 % (AUC_{0-∞} ratio x 100 %, range 49 - 97 %). The mean (SD) peak concentration of dexmedetomidine in plasma was 0.30 (0.10) ng/ml, and plasma levels associated with sedative effects (i.e > 0.20 ng/ml) for 4 hours after SC dosing. Plasma noradrenaline levels were significantly lower (P < 0.001) after IV than after SC administration. Subjective scores for vigilance and performance were significantly lower 0-60 min after IV than SC dosing (P < 0.001 for both). The onset of the cardiovascular, sympatholytic and sedative effects of dexmedetomidine were clearly less abrupt after SC than IV administration.</p> <p>Conclusions: Dexmedetomidine is relatively rapidly and efficiently absorbed after SC administration. Subcutaneous dexmedetomidine may be a feasible alternative in palliative sedation, and causes attenuated cardiovascular effects compared to IV administration.</p>	
Corresponding Author:	Panu Uusalo Turku University Hospital Turku, FINLAND	
Corresponding Author Secondary Information:		
Corresponding Author's Institution:	Turku University Hospital	
Corresponding Author's Secondary Institution:		
First Author:	Panu Uusalo	
First Author Secondary Information:		
Order of Authors:	Panu Uusalo Ida Tilli Darin Al-Ramahi	

	Riku Aantaa
	Mika Scheinin, Professor
	Teijo Saari, Professor
Order of Authors Secondary Information:	
Author Comments:	<p>Dear Recipient,</p> <p>this is first study investigating pharmacokinetics of subcutaneously given dexmedetomidine. I kindly hope that You accept my manuscript.</p> <p>Sincerely Yours Dr. Panu Uusalo</p>
Suggested Reviewers:	<p>Maud Weerink PhD Candidate in Anesthesiology, Rijksuniversiteit Groningen m.a.s.weerink@umcg.nl Recent review on pharmacokinetics of dexmedetomidine.</p>

[Click here to view linked References](#)

Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers

Uusalo P^{1,2*}, Al-Ramahi D³, Tilli I¹, Aantaa RA^{2†}, Scheinin M³, Saari TI^{1,2}

¹Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland

²Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, Turku, Finland,

³Institute of Biomedicine, University of Turku, and Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland

*Corresponding author: Panu Uusalo MD, Department of Anaesthesiology and Intensive Care, University of Turku, P.O. Box 51 (Kiinamylynkatu 4-8), FI-20521 Turku, Finland, e-mail: pijuus@utu.fi, tel: +358 2 313 0000, Orcid-ID 0000-0001-5120-8854

†Demised

ABSTRACT

Purpose: Palliative care patients often need sedation to alleviate intractable anxiety, stress and pain.

Dexmedetomidine is used for sedation of intensive care patients, but there is no prior information on its subcutaneous (SC) administration, a route that would be favored in palliative care. We compared the pharmacokinetics and cardiovascular, sympatholytic and sedative effects of SC and intravenously (IV) administered dexmedetomidine in healthy volunteers.

Methods: An open two-period, cross-over design with balanced randomization was used. Ten male subjects received 1 µg/kg dexmedetomidine both IV and SC. Concentrations of dexmedetomidine and catecholamines in plasma were measured. Pharmacokinetic variables were calculated with non-compartmental methods. In addition, cardiovascular and sedative drug effects were monitored.

Results: Peak concentrations of dexmedetomidine were observed 15 min after SC administration (median; range 15-240). The mean bioavailability of SC dexmedetomidine was 81 % (AUC_{0-∞} ratio x 100 %, range 49 - 97 %). The mean (SD) peak concentration of dexmedetomidine in plasma was 0.30 (0.10) ng/ml, and plasma levels associated with sedative effects (i.e > 0.20 ng/ml) for 4 hours after SC dosing. Plasma noradrenaline levels were significantly lower (P < 0.001) after IV than after SC administration. Subjective scores for vigilance and performance were significantly lower 0-60 min after IV than SC dosing (P < 0.001 for both). The onset of the cardiovascular, sympatholytic and sedative effects of dexmedetomidine were clearly less abrupt after SC than IV administration.

Conclusions: Dexmedetomidine is relatively rapidly and efficiently absorbed after SC administration. Subcutaneous dexmedetomidine may be a feasible alternative in palliative sedation, and causes attenuated cardiovascular effects compared to IV administration.

Keywords: Dexmedetomidine, Subcutaneous, Pharmacokinetics, Palliative care

ClinicalTrials.gov Identifier: NCT02724098. EUDRA CT number 2015-004698-34.

INTRODUCTION

1
2
3 Patients in palliative end-of-life care often suffer from intractable anxiety, stress and pain, and may
4
5 need pharmacological sedation. Such symptoms are commonly managed with opioids,
6
7 benzodiazepines, antidepressants or antipsychotic drugs (1). As all of these agents have dose-related
8
9 adverse effects, combinations are often used to decrease individual drug doses or for beneficial
10
11 synergistic interactions. The use of opioids is associated with many adverse effects such as nausea,
12
13 vomiting, constipation, and most importantly, respiratory depression (1-2). Benzodiazepines are
14
15 efficacious sedatives but lack analgesic activity and may provoke delirium (3). Thus, there is a
16
17 clinical need for alternative treatments to alleviate end-of-life symptoms.
18
19
20
21
22
23

24 α_2 -Adrenoceptor agonists, in clinical use best exemplified by dexmedetomidine, are distinct in their
25
26 mechanism of action from other clinically available analgesic and sedative agents (4-5).
27
28 Dexmedetomidine has been demonstrated to induce dose-dependent sedation without major risk of
29
30 ventilatory depression (6-8). Dexmedetomidine is also known to attenuate hemodynamic and
31
32 endocrine stress responses (9-11).
33
34
35
36

37 Dexmedetomidine is in clinical use in more than 70 countries for sedation of adult intensive care
38
39 unit (ICU) patients. In some countries, it also has regulatory approval for perioperative sedation
40
41 (12). Based on its pharmacological mechanism of action and on several published case reports and
42
43 uncontrolled studies, dexmedetomidine may provide benefits for patients in palliative care as it
44
45 induces analgesia, sympatholysis and sleep-like sedation with relatively little risk of respiratory
46
47 depression. Of note, dexmedetomidine-induced sedation is also associated with arousability, thus
48
49 allowing the patient to communicate and remain in contact with family and caregivers (13-14).
50
51 Confusion and delirium are seldom seen in ICU patients receiving dexmedetomidine, which
52
53 contrasts with e.g. benzodiazepines and propofol (3, 15). Furthermore, dexmedetomidine has
54
55 beneficial synergistic interactions with opioids and other sedative drugs. Dexmedetomidine is well
56
57
58
59
60
61
62
63
64
65

absorbed when administered intranasally (IN) (16), intramuscularly or buccally (17-19). However,
there are no published reports on its pharmacokinetics after subcutaneous (SC) administration.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

MATERIALS AND METHODS

Subjects and ethics

The study protocol (EudraCT 2015-004698-34, ClinicalTrials.gov identifier NCT02724098) conformed to the revised Declaration of Helsinki (20), and was approved by the Ethics Committee of the Hospital District of Southwest Finland and by the Finnish National Agency for Medicines. Written informed consent was obtained from eleven male subjects aged between 18 and 30 years. Their mean (SD) age and body mass index (BMI) were 22.6 (2.2) years and 23,9 (1,5) kg m⁻², respectively. Concomitant medications (except occasional paracetamol), current or recent significant illness, history of any kind of drug allergy or previous or present alcohol dependence, drug abuse, psychological or other emotional problems likely to invalidate informed consent or to limit the ability of the subject to comply with the protocol requirements were exclusion criteria.

Study design

The study was conducted according to a two-period cross-over design with balanced randomization. The study days were separated by three weeks. On the study days, subjects fasted from midnight until 5 h after drug administration. Water intake was allowed. Each study session was performed from 07:30 a.m. to 18:30 p.m. The subjects remained in a semi-recumbent position after cannulation until the end of the session, excluding bio-breaks (meals, toilet visits). Standard meals were served 5 and 9 h after dexmedetomidine administration.

The subjects were scheduled to receive 1 µg/kg doses of dexmedetomidine IV and SC in randomized order. IV doses of dexmedetomidine (Dexdor® 100 µg/ml, Orion Pharma, Espoo, Finland) were diluted in 0.9 % saline solution (Natriumchlorid B. Braun® 9 mg/ml, B. Braun, Melsungen, Germany) and administered at a concentration of 8 µg/ml during 10 min by infusion (Perfusor® Space Infusion Pump, B. Braun). SC dexmedetomidine (Dexdor® 100 µg/ml) was

1 diluted in 0.9 % saline solution and administered at a concentration of 50 µg/ml during 10 min by
2 infusion with the same pump.
3
4

5 *Sampling*

6
7
8

9 At the start of each study session, a venous catheter was inserted into a large forearm vein for safety
10 reasons. An arterial catheter was inserted into a radial artery for blood sampling and blood pressure
11 monitoring. Peripheral oxygen saturation was measured with pulse oximetry. Arterial blood
12 samples (blood volume 5 ml) were collected immediately prior to administration of
13 dexmedetomidine (baseline) and then at 5, 10, 15, 20, 30, 45 min and 1, 1.5, 2 and 3 h after the start
14 of the 10-min infusions into EDTA tubes for determination of concentrations of dexmedetomidine,
15 adrenaline and noradrenaline in plasma. Further blood samples were collected at 4, 5, 6, 8 and 10 h
16 for determination of dexmedetomidine. The samples were chilled in ice. Plasma was separated by
17 centrifugation in a refrigerated centrifuge and samples were stored at -70 °C.
18
19
20
21
22
23
24
25
26
27
28
29
30

31 *Dexmedetomidine and catecholamine analysis*

32
33
34

35 Concentrations of dexmedetomidine in plasma were determined with a validated (21) reversed-
36 phase high-performance liquid chromatography method with tandem mass spectrometric detection
37 (HPLC-MS/MS; Shimadzu Prominence HPLC connected to an AB Sciex API4000 mass
38 spectrometer), with some modifications to a previously described procedure (22). Solid-phase
39 extraction was performed with Sep-Pak® tC18 cartridges (Waters Corporation, Milford, MA,
40 USA), and deuterium-labelled dexmedetomidine (from Toronto Research Chemicals, Toronto, ON,
41 Canada) was used as the internal standard. The mobile phase was 0.1 % formic acid in a mixture of
42 1:1:1 (v/v/v) methanol/acetonitrile/water. The lower limit of quantitation (LLOQ) was 0.05 ng/ml.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 (23), but now adapted to a dedicated HPLC system provided by Thermo Fisher Scientific
2 (Waltham, MA, USA). The analytical column was a reversed-phase C18 column (HR-80 C1), the
3
4 detector was a Dionex Ultimate ECD-3000RS instrument coupled to a model 6011RS Ultra dual
5
6 electrode, and the system was operated with Chromeleon v. 7 software (all from Thermo Fisher
7
8 Scientific). The LLOQ for both catecholamines was 0.1 nM. The within- and between-run precision
9
10 of the assay (coefficient of variation) was within 10 % in the relevant concentration range.
11
12
13
14

15 *Pharmacokinetic analysis*

16
17
18 Data were log-transformed before statistical analysis, but non-transformed results are reported. The
19
20 peak plasma concentrations (C_{\max}) and corresponding peak plasma concentration times (t_{\max}) were
21
22 observed directly from the data. For each subject, the terminal log-linear phase of the plasma
23
24 dexmedetomidine concentration-time curve was identified visually, and the elimination rate
25
26 constant (k_{e1}) was determined by regression analysis on the basis of at least four time points. The
27
28 elimination half-life ($t_{1/2}$) was then calculated from the equation $t_{1/2} = \ln 2 / k_{e1}$. The area under
29
30 the dexmedetomidine plasma concentration-time curve (AUC) was calculated using the trapezoidal
31
32 method, with the linear trapezoidal rule for increasing concentrations and the logarithmic
33
34 trapezoidal rule for decreasing concentrations. Apparent clearance (CL/F) and apparent volume of
35
36 distribution of dexmedetomidine during the elimination phase (V_z/F) were also calculated, with
37
38 non-compartmental methods based on statistical moment theory. The pharmacokinetic analysis was
39
40 carried out with WinNonlin software (version 4.1, Pharsight Corporation, Mountain View, CA,
41
42 USA).
43
44
45
46
47
48
49
50
51

52 *Pharmacodynamic measurements*

53
54
55
56 Heart rate, intra-arterial blood pressure and peripheral oxygen saturation were recorded at times of
57
58 blood sampling (immediately prior to administration of dexmedetomidine (baseline) and thereafter
59
60
61
62
63
64
65

1 at 5, 10, 15, 30 and 45 min and 1, 1.5, 2, 3, 5, 8 and 10 h after the start of dexmedetomidine
2 administration). At the same time points, also psychomotor drug effects on vigilance and
3
4 performance were assessed with visual analog scales (VAS). Subjective assessments (alert to
5
6 drowsy, very good performance to very poor performance) were recorded with 100 mm horizontal
7
8 VAS lines. For each pharmacodynamic variable, the AUC was determined using the trapezoidal
9
10 rule.
11
12

13 *Assessment of local tolerability*

14
15
16 The local tolerability of SC and IV administered dexmedetomidine was assessed with VAS scores
17
18 by the study participants and by visual inspection by the investigator immediately prior to drug
19
20 administration (baseline) and at 1, 5, and 10 h. Subjective effects (no local pain/strong pain, no
21
22 irritation/strong irritation, no pruritus/strong pruritus, no numbness/total numbness) were recorded.
23
24 In the visual inspection by the investigator, possible local dermal irritation, inflammation, bleeding
25
26 and swelling were recorded. For each assessment, the AUC was calculated using the trapezoidal
27
28 rule.
29
30
31
32
33
34
35

36 *Statistical analysis*

37
38
39 In view of previous studies (16-17), we calculated that 8 subjects would be needed to detect a 30 %
40
41 difference in the AUC of plasma dexmedetomidine at a power of 80 % and a level of significance
42
43 of $P < 0.05$. To be prepared for drop-outs, we recruited 10 subjects. The primary outcome variables
44
45 of this study were the observed concentrations of dexmedetomidine in plasma and its calculated
46
47 pharmacokinetic parameters. The secondary variables were heart rate, blood pressure, plasma
48
49 adrenaline and noradrenaline concentrations, sedative effects, and possible local adverse effects.
50
51 The data were evaluated for normality of distributions with probit plots and the Shapiro–Wilk’s W-
52
53 test. Log-transformed data were analyzed but non-transformed results are reported. Differences in
54
55 pharmacokinetic variables were analyzed using paired t tests. Pharmacodynamic data were analyzed
56
57
58
59
60
61
62
63
64
65

1 using analysis of variance (ANOVA) for repeated measurements. The results are expressed as mean
2 values and SD, except for t_{\max} , which is expressed as median (range). Explorative data analysis and
3
4 statistical testing was performed using R language for Statistical Computing, version 3.3.2 (24), in
5
6 RStudio, version 1.0.136 (25).
7
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

RESULTS

1
2
3 Ten male subjects (aged 19 to 27 y) were recruited, of whom eight completed the study. Eight
4 subjects received both SC and IV dexmedetomidine and another two subjects received only SC
5 dexmedetomidine. One subject missed his IV study session for personal reasons. Another subject
6 was withdrawn from the study as a safety measure after the SC administration phase due to
7 emergence of bradycardia of 32-39/min, at 1-5 h after drug administration; the bradycardia was not
8 associated with subjective symptoms and resolved with no interventions. Calculations were based
9 on 10 and 8 subjects during the SC and IV phases, respectively.

10
11 Instead of bolus dosing, we administered dexmedetomidine as 10-min infusions to avoid α_2 -
12 adrenoceptor-mediated vasoconstriction and hypertension that may ensue after rapid IV
13 administration (26). Due to technical issues with infusion pumps, one participant received 1.07
14 $\mu\text{g}/\text{kg}$ of dexmedetomidine during 11 min 42 s on both occasions and one participant received 0.78
15 $\mu\text{g}/\text{kg}$ of SC dexmedetomidine during 7 min 47 s. All other dosages were 1 $\mu\text{g}/\text{kg}$ and were given
16 during 10 minutes. Drug concentration analysis resulted in 3 (2 %) and 8 (7 %) observed
17 dexmedetomidine concentrations $<\text{LLOQ}$ after IV and SC dosing, respectively. During the IV
18 phase, 12 (12 %) of the noradrenaline concentrations were $<\text{LLOQ}$. For adrenaline, there were 38
19 (43 %) and 25 (23 %) measurements $<\text{LLOQ}$ during the IV and SC phases, respectively.
20 Concentration values $<\text{LLOQ}$ were included in the calculations as equal to 50 % of the LLOQ, i.e.
21 0.025 ng/ml and 0.05 nM for dexmedetomidine and catecholamines, respectively.

Pharmacokinetic results

22
23 The calculated pharmacokinetic parameters are shown in Table 1 and mean (SD) plasma
24 concentrations of dexmedetomidine are shown in Fig. 1. The mean (SD) peak concentration of
25 dexmedetomidine in plasma was 0.30 (0.10) ng/ml after SC administration, and plasma levels
26 previously associated with sedative effects (i.e. >0.20 ng/ml (6, 27) were maintained for 4 hours
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 after SC dosing. After IV administration, the mean C_{max} of dexmedetomidine was 2.42 ng/ml,
2 observed at the end of the IV infusion. Peak concentrations of dexmedetomidine in plasma were
3
4 observed 15 min after the end of the SC infusion (median; range 15-240 min). After 3 hours, similar
5
6 plasma concentrations were measured during both study phases. The mean exposure ($AUC_{0-\infty}$) to
7
8 dexmedetomidine was 36 % lower during the SC phase, but apparent mean $t_{1/2}$ was prolonged
9
10 compared to the IV phase (1.9 h vs. 3.8 h, $P < 0.001$). The mean bioavailability of SC
11
12 dexmedetomidine was 81 % (range 49 to 97 %).
13
14
15
16

17 *Pharmacodynamics*

18
19
20
21 There was a slight but statistically insignificant increase in mean arterial pressure (MAP) at the end
22
23 of the IV infusion. Compared to the SC phase, mean MAP was significantly lower during 0-120
24
25 min ($P < 0.032$) after IV administration of dexmedetomidine (Fig. 2). Although heart rate decreased
26
27 initially after IV dosing, there were no statistically significant differences between the treatments
28
29 when maximum decreases or epochs over 0-30 or 0-60 min after drug administration were tested.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Peripheral oxygen saturation remained unchanged during both phases in each subject.

66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Subjective effects of dexmedetomidine are shown in Fig. 4. Scores for vigilance and performance were significantly lower at 0-60 min after IV than after SC dosing ($P < 0.001$ for both effects), but

at later time points, the subjects tended to be more sedated after SC than after IV administration.

The performance scores were actually statistically significantly lower during the SC phase for the 60-600 min observation period ($P = 0.023$), but there was no significant difference in the vigilance scores during this period.

Local tolerability

There were no visible signs of local skin irritation at the infusion sites. No subjective local or systemic adverse events were reported.

DISCUSSION

1
2
3 We compared the pharmacokinetics of SC and IV administered dexmedetomidine with doses
4
5 previously suggested for palliative sedation (28-29). We hypothesized that the bioavailability of SC
6
7 dexmedetomidine would be sufficient for palliative dosing and that the hemodynamic side-effects
8
9 of dexmedetomidine might be reduced by this route of administration because of slower entry of the
10
11 drug into the systemic circulation compared to IV administration as a 10-min infusion. Our results
12
13 show that the bioavailability of SC dexmedetomidine is sufficient for clinical utility, even if marked
14
15 inter-individual variability was observed.
16
17
18
19
20

21 High peak concentrations in plasma were avoided by SC dosing, but after 3 hours, similar plasma
22
23 concentrations were measured during both study phases. The exposure was 31% smaller during the
24
25 SC phase during the sampling time ($AUC_{0-10\text{ h}}$) compared to the IV phase. When based on $AUC_{0-\infty}$,
26
27 the mean relative bioavailability of SC dexmedetomidine was 81 %. The pharmacokinetic
28
29 parameters determined for IV dexmedetomidine were similar to those reported earlier (29).
30
31
32
33

34 In line with the pharmacokinetic results, the hemodynamic, sympatholytic and sedative effects of
35
36 dexmedetomidine emerged significantly less abruptly after SC dosing when compared with IV
37
38 administration. Previous studies have demonstrated that IV dexmedetomidine causes dose-
39
40 dependent decreases in heart rate and blood pressure, with initial hypertension after larger doses,
41
42 concomitantly with decreases in plasma catecholamines (6, 30-31). We wanted to diminish
43
44 dexmedetomidine-induced bradycardia in the IV phase by administering 10-min constant-rate
45
46 infusions, but IV dosing still resulted in significant decreases in heart rate and blood pressure.
47
48
49
50
51 Compared to this, SC administration was associated with sustained and much smaller reductions,
52
53 and may thus reduce the risk of hemodynamic depression compared with IV dosing.
54
55
56

57 One participant had asymptomatic bradycardia of 32-39/min from 60 to 300 min after SC
58
59 administration of dexmedetomidine. He was an athlete with low resting heart rate of 40-42/min.
60
61
62
63
64
65

1 The results of previous studies indicate that dexmedetomidine causes significant cardiac conduction
2 effects via depression of the sino-atrial node, thus decreasing resting heart rate by up to 15-20 %
3
4 (7). We therefore excluded this subject from the IV part of the study, in order to avoid the risk of
5
6 severe bradycardia. Apart from the observed hemodynamic changes, the subjects had no significant
7
8 adverse effects. We did not record any changes in oxygen saturation. Similarly, with the
9
10 hemodynamic effects, the onset of subjective sedation was delayed after SC dexmedetomidine
11
12 compared to IV administration. Our results thus indicate that the sedative effects of SC
13
14 dexmedetomidine may appear less abruptly and last longer compared to IV dosing. This could be
15
16 beneficial when providing prolonged sedation for patients in palliative care, obviating the need for
17
18 IV drug infusions. Our results thus suggest that SC dexmedetomidine might be an efficacious and
19
20 safe addition to drugs used for palliative sedation. However, we investigated healthy volunteers,
21
22 and no placebo control session was included in the study. Therefore, these findings should be
23
24 considered as preliminary, and further studies are warranted.
25
26
27
28
29
30

31
32 Bioavailability of dexmedetomidine after intranasal, intramuscular, oral and buccal administration
33
34 has been investigated previously (16-18). Our current findings suggest approximately similar
35
36 bioavailability of dexmedetomidine after SC, IN and IM administration, and confirm that the
37
38 bioavailability is sufficient for clinical usefulness also after SC administration. Further studies are,
39
40 however, needed to warrant this administration route in clinical practice. Our study was conducted
41
42 with a small number of healthy volunteer subjects. We collected plasma samples for the
43
44 concentration measurements for 10 hours, which was reflected in the fraction of the extrapolated
45
46 area (mean 28 %) in the area under the plasma concentration-time curve to infinity ($AUC_{0-\infty}$)
47
48 during the SC phase.
49
50
51
52
53
54

55
56 Our study participants reported no subjective local adverse effects related to SC administration of
57
58 dexmedetomidine. We could not see any local irritation of the skin around the SC dosing area.
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

However, in five subjects the area of drug administration felt slightly numb during the sampling phase, which is probably related to α_2 -adrenoceptor mediated vasoconstriction caused by dexmedetomidine. These findings suggest that the SC route may be a safe mode to dose dexmedetomidine.

SC dexmedetomidine has been used in palliative care, but such use has only been described in some uncontrolled case reports (32-33). Dexmedetomidine has several beneficial pharmacological characteristics, it has a relatively short half-life, and it provides sedation that is associated with easy arousability. Furthermore, dexmedetomidine has opioid-sparing effects and it may reduce the likelihood of delirium, at least when compared to sedation with propofol or benzodiazepines. Further work is required to examine its possible role and utility in the management of terminal sedation in palliative care.

CONCLUSION

Dexmedetomidine is rapidly and efficiently absorbed after SC administration. Compared to IV administration, SC administration of dexmedetomidine may be a feasible alternative for patients requiring sedation.

ACKNOWLEDGMENTS

We thank Mrs. Elina Kahra (medical laboratory technologist, Clinical Pharmacology, TYKSLAB, Hospital District of Southwest Finland, Turku, Finland) for her skillful technical assistance. This study was supported financially by Turku University Hospital research fund (EVO grants 13693 and 13821), Turku, Finland.

CONFLICT OF INTERESTS

1 M. Scheinin has been engaged in contract research for Orion Pharma, the manufacturer of
2 dexmedetomidine. T. Saari has received honoraria for speaking at symposia organized by Orion
3
4 Pharma. P. Uusalo has received speaker fee from Orion Pharma. The other authors declare that they
5
6 have no conflicts of interest.
7
8
9

10 11 12 13 14 **AUTHOR'S CONTRIBUTIONS** 15 16

17
18 Panu Uusalo took care of the clinical phase of the study and data collection, participated in data
19
20 analysis and statistical analysis and wrote the manuscript. Darin Al-Ramahi performed the
21
22 analytical assays. Ida Tilli took care of the clinical phase of the study and data collection,
23
24 participated in data analysis. Riku Aantaa designed the study, wrote the protocol, supervised and
25
26 coordinated the clinical implementation of the study, and participated in data analysis. Mika
27
28 Scheinin supervised the analytical assays, participated in data analysis and statistical analysis and
29
30 wrote the manuscript.. Teijo Saari designed the study, analyzed the data, performed data and
31
32 statistical analysis, and wrote the manuscript. All authors materially participated in the research
33
34 and/or manuscript preparation. All authors have contributed to and approved the final manuscript.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

FIGURE LEGENDS

1
2
3 **Fig. 1** Mean (SD) dexmedetomidine concentrations in plasma after administration of 1 µg/kg of
4 dexmedetomidine intravenously (closed circles) to eight or subcutaneously (open circles) to ten
5
6 healthy volunteers. The concentrations are shown both on arithmetic and logarithmic scales (inset).
7
8
9

10
11 **Fig. 2** Heart rate and mean blood pressure; mean (SD) after administration of 1 µg/kg of
12 dexmedetomidine intravenously (closed circles) or subcutaneously (open circles) to eight and ten
13
14 healthy male volunteers, respectively. MAP Mean arterial pressure.
15
16
17
18
19

20 **Fig. 3** Mean (SD) adrenaline and noradrenaline concentrations in plasma after administration of 1
21 µg/kg of dexmedetomidine intravenously (closed circles) to eight or subcutaneously (open circles)
22
23 to ten healthy male volunteers.
24
25
26
27

28 **Fig. 4** Mean (SD) subjective assessment scores (vigilance and performance, visual analog scales,
29 VAS) after administration of 1 µg/kg of dexmedetomidine intravenously (closed circles) to eight or
30
31 subcutaneously (open circles) to ten healthy male volunteers.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

REFERENCES

1. Devlin JW, Roberts RJ (2011) Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids. *Anesthesiol Clin* 29(4):567-85
2. Barr J, Zomorodi K, Bertaccini EJ, Shafer SL, Geller E (2001) A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. *Anesthesiology* 95(2):286-98
3. Pandharipande P, Shintani A, Peterson J (2006). Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. *Anesthesiology* 104(1): 21-26
4. Wujtewicz M, Maciejewski D, Misiólek H, Fijałkowska A, Gaszyński T, Knapik P, Lango R (2013) Use of dexmedetomidine in the adult intensive care unit. *Anaesthesiol Intensive Ther* 45(4):235-40
5. Aantaa R, Tonner P, Conti G, Longrois D, Mantz J, Mulier JP (2015) Sedation options for the morbidly obese intensive care unit patient: a concise survey and an agenda for development. *Multidiscip Respir Med* 10(1):8
6. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colino MD (2000) The effects of increasing plasma concentrations of dexmedetomidine in humans. *Anesthesiology* 93(2):382-94
7. Lodenius Å, Ebberyd A, Hårdemark Cedborg A, Hagel E, Mkrtchian S, Christensson E, Ullman J, Scheinin M, Eriksson LI, Jonsson Fagerlund M. (2016) Sedation with dexmedetomidine or propofol impairs hypoxic control of breathing in healthy male volunteers: a nonblinded, randomized crossover study. *Anesthesiology* 125:700-15
8. Petroz GC, Sikich N, James M, van Dyk H, Shafer SL, Schily M, Lerman J (2006) A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. *Anesthesiology* 105(6):1098-110

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
9. Scheinin B, Lindgren L, Randell T, Scheinin H, Scheinin M (1992) Dexmedetomidine attenuates sympathoadrenal responses to tracheal intubation and reduces the need for thiopentone and perioperative fentanyl. *Br J Anaesth.* 68(2):126-31
10. Talke P, Li J, Jain U, Leung J, Drasner K, Hollenberg M, Mangano DT. (1995) Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. The Study of Perioperative Ischemia Research Group. *Anesthesiology.* 82(3):620-33
11. Patel CR, Engineer SR, Shah BJ, Madhu S (2012) Effect of intravenous infusion of dexmedetomidine on perioperative haemodynamic changes and postoperative recovery: A study with entropy analysis. *Indian J Anaesth* 56(6):542-6
12. Dexdor SPC (2014). URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002268/WC500115631.pdf
13. Gupta S, Singh D, Sood D, Kathuria S (2015) Role of dexmedetomidine in early extubation of the intensive care unit patients. *J Anaesthesiol Clin Pharmacol* 31(1):92-8
14. Pichot C, Ghignone M, Quintin L (2012) Dexmedetomidine and clonidine: from second- to first-line sedative agents in the critical care setting? *J Intensive Care Med* 27(4):219-37
15. Gadalla F, Spencer J (1996) Prolonged delirium after propofol. *Can J Anaesth*, 43:87
16. Iiro T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, Olkkola KT (2011) Bioavailability of dexmedetomidine after intranasal administration. *Eur J Clin Pharmacol* 67(8):825-31
17. Scheinin H, Karhuvaara S, Olkkola KT, Kallio A, Anttila M, Vuorilehto L, Scheinin M (1992) Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. *Clin Pharmacol Ther* 52(5):537-46

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
18. Anttila M, Penttilä J, Helminen A, Vuorilehto L, Scheinin H (2003) Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. *Br J Clin Pharmacol.* 56(6):691-3
 19. Cimen ZS, Hanci A, Sivrikaya GU, Kilinc LT, Erol MK (2013) Comparison of buccal and nasal dexmedetomidine premedication for pediatric patients. *Paediatr Anaesth* 23(2):134-138
 20. Declaration of Helsinki (2013) URL <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>
 21. Guidance for Industry Bioanalytical Method Validation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM) (2001) URL <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf>
 22. Ji QC, Zhou JY, Gonzales RJ, Gage EM, El-Shourbagy TA (2004) Simultaneous quantitation of dexmedetomidine and glucuronide metabolites (G-Dex-1 and G-Dex-2) in human plasma utilizing liquid chromatography with tandem mass spectrometric detection. *Rapid Commun Mass Spectrom* 18(15):1753–1760
 23. Scheinin M, Karhuvaara S, Ojala-Karlsson P, Kallio A, Koulu M (1991) Plasma 3, 4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of alpha 2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. *Life Sci* 49(1):75–84
 24. R Core Team (2017) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>
 25. RStudio Team (2016). RStudio: Integrated Development for R. RStudio, Inc., Boston, MA URL <http://www.rstudio.com/>

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
26. Gertler R, Brown HC, Mitchell DH, Silvius EN (2001). Dexmedetomidine: a novel sedative-analgesic agent. *Proc (Bayl Univ Med Cent)* 14(1):13-21
 27. Bloor BC, Ward DS, Belleville JP, Maze M (1992). Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. *Anesthesiology* 77:1134-42.
 28. Kent CD, Kaufman BS, Lowy J (2005) Dexmedetomidine facilitates the withdrawal of ventilatory support in palliative care. *Anesthesiology* 103(2):439-441
 29. Soares LG, Naylor C, Martins MA, Peixoto G (2002) Dexmedetomidine: a new option for intractable distress in the dying. *J Pain Symptom Manage* 24(1):6-8
Snapir A, Posti J, Kentala E, Koskenvuo J, Sundell J, Tuunanen H, Hakala K, Scheinin H, Knuuti J, Scheinin M (2006) Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. *Anesthesiology* 105(5):902-10
 30. Kallio, A., Scheinin, M., Koulu, M., Ponkilainen, R., Ruskoaho, H., Viinamäki, O. et al. (1989). Effects of dexmedetomidine, a selective alpha 2-adrenoceptor agonist, on hemodynamic control mechanisms. *Clin Pharmacol Ther*, 46(1), 33-42
 31. Hilliard N, Brown S, Mitchinson S (2015) A case report of dexmedetomidine used to treat intractable pain and delirium in a tertiary palliative care unit. *Palliat Med* 29(3):278-281
 32. O'Hara C, Tamburro RF, Ceneviva GD (2015) Dexmedetomidine for sedation during withdrawal of support. *Palliat Care* 9:15-8

Table 1. Pharmacokinetic parameters after 1 µg/kg dose¹ of dexmedetomidine administered intravenously and subcutaneously in 10 healthy volunteers.

Parameter	Intravenous	Subcutaneous	P-value
C _{max} (ng/ml)	2.42 (0.36)	0.30 (0.1)	< 0.001
t _{max} (h)	0.17 (0.08-0.17)	0.25 (0.25-4)	0.013
AUC ₀₋₁₀ (ng·min/l)	117.3 (20.2)	74.4 (21.2)	< 0.001
AUC _{0-∞}	120.5 (21.0)	108.5 (40.0) ²	0.004
CL/F (l/hr)	-	54.2	-
V _z /F (l)	-	92.8 (9.9)	-
CL (l/hr)	40.6	-	-
V _{ss} (l)	92.8 (9.9)	-	-
t _{1/2} (min)	1.9 (0.25)	3.8 (0.89)	< 0.001
F (%) ³	-	80.9 (48.6-96.6)	-

Data are given as mean and SD, except for t_{max} data, which are given as median and range.

C_{max}, peak plasma concentration; t_{max}, time to peak plasma concentration; AUC₀₋₁₀, area under dexmedetomidine plasma concentration–time curve 0 to 10 hours after dexmedetomidine dose; AUC_{0-∞}, area under dexmedetomidine plasma concentration–time curve extrapolated to infinity; CL/F, Apparent oral clearance; V_z/F, apparent volume of distribution during elimination; CL, plasma clearance of midazolam; V_{ss}, steady-state volume of distribution; F, oral bioavailability; t_{1/2}, elimination half-life.

¹Dose was given as a 10 minutes long constant infusion

²In average, 28.6% (12.2) of AUC_{0-∞} was extrapolated

³Calculation of subcutaneous bioavailability was based on 8 subjects







